Clinical Trials for Campylobacter Infections

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Campylobacter Infections from the ClinicalTrials.gov database.

Trial Summary

• Total studies: 17
• Recruiting: 1
• Active, not recruiting: 0
• Completed: 10
• Other: 6

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT03223077 — Mucosal and Microbiota Changes During Acute Campylobacteriosis

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help ide…

Completed Trials

NCT00742469 — Rifaximin for Prevention of Travellers’ Diarrhea

The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers’ diarrhea compared to placebo.

NCT02067676 — Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant. This study will also assess immune responses induced by the vaccine.

NCT02105714 — Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders

NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system for delivering primary health care in resource-constrained settings. NIDIAG will investigate three clinical syndromes, namely (i) persistent digestive disorders, (ii) persistent fever and (iii) neurological disor…

NCT02280044 — Efficacy of Rifaximin in Preventing Campylobacteriosis

This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.

NCT02884752 — Retrospective Study of Bone Infection Due to Campylobacter Spp

Only 24 cases of Campylobacter bone and joint infection (BJI) have been reported worldwide between 1955 and 2008. Between 2010 and 2012, 7 cases were observed in two University hospitals in France. This increasing number of cases raises several issues. Are they the consequences of better detections and reporting, or are they reflecting any epidemiologic changes? For answering these questions, w…

NCT03266068 — Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders

Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long after the acute infection is over. The exact reason why certain individuals develop these symptoms whereas others don’t is not exactly clear.

The researchers are study…

NCT03683667 — Protein Plus: Improving Infant Growth Through Diet and Enteric Health

This cluster-randomized controlled trial is designed to address linear growth faltering in 6-12-mo-old Bangladesh infants through a proof-of-concept package of interventions to a) increase intake of high quality protein and b) control enteric pathogens.

NCT04098263 — Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single dose or at one of three dose levels three times daily over 28 days. Protocol-specified evaluations and procedures will be performed on Days 1-2 and every one-two weeks during dosing. Study observation will conti…

NCT04182490 — LMN-101 in a Campylobacter Human Challenge Model

Randomized, double-blind, placebo-controlled, single dose regimen study of LMN-101 followed by Campylobacter jejuni challenge. Subjects will initially, after documentation of informed consent, begin taking their assigned LMN-101 or placebo regimen three times daily. After two days, subjects will receive the C. jejuni challenge inoculum. Subjects will begin an appropriate antibiotic course upon …

NCT05500417 — Safety and Immunogenicity of CJCV2 With and Without ALFQ

This is a randomized, double-blind, dose-escalating, outpatient trial in a total of approximately 60 subjects, assigned to 3 cohorts (20 subjects per cohort). Each subject will receive one of three intramuscular (IM) vaccinations, spaced 28 days apart, of Campylobacter jejuni Conjugate Vaccine (CJCV2) with or without a fixed dose of the adjuvant Army Liposome Formulation containing QS-21 (ALFQ)…

Other (Unknown)

NCT00434798 — Campylobacter Jejuni Challenge Model Development: Dose Ranging Study

The primary objective of this study is to establish a human Campylobacter jejuni infection model with the following characteristics:

1. Safe application

   1. Infectious period risk mitigated by close monitoring and prospectively applied early treatment criteria
   2. Potential post-infectious sequelae risk mitigated by appropriate strain and host selection

2. Campylobacteriosis attack rate o…

NCT00859716 — ACE393-103 Vaccination Challenge Study

The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.

NCT01048112 — Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection

The goal of this research is to continue to develop a model of infection with Campylobacter jejuni, a bacterium that causes food and water-borne disease (mainly diarrhea). The objectives are to 1) determine if healthy subjects develop short-term (<6 month) protection to reinfection with C. jejuni; and 2) characterize the immune responses to C. jejuni infection. Information obtained will be use…

NCT02040922 — Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota

The principal research objective is to determine the impact of antibiotic use on the risk of developing long term bowel symptoms after infection with the germ Campylobacter.

NCT06425250 — Campylobacter Spp. Bone and Joint Infection: a Retrospective Cohort Study

Campylobacter bacteria, a Gram-negative bacillus commensal in the digestive tract of many animals and mainly responsible for human infections with digestive origins, has been little studied in the field of osteoarticular infections (OAI). Campylobacter spp. are, however, well described, mainly for C. fetus, and pose a dual therapeutic problem: i) a capacity for persistence due to the capacity o…

NCT06432777 — Recurrent Campylobacter Bacteraemia in Immunocompromised Patients

Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples.

As of today, only around 20 cases have been described in the international literature for the last 30 years. The cases are likely highly underreported.

No study describes those recurrent Campylobacter bacteraemias at the sca…